Actively Recruiting
Evaluating Monthly Berobenatide Compared to Weekly Semaglutide or Tirzepatide to Maintain Weight Loss in Adults with Overweight or Obesity
Led by Pfizer · Updated on 2026-10-15
660
Participants Needed
16
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This research evaluates the safety and effectiveness of berobenatide in adults who are overweight or have obesity and have already lost weight while using semaglutide or tirzepatide. The study specifically excludes people with diabetes and aims to understand how well berobenatide helps maintain weight loss. It is a phase 3 randomized trial sponsored by Pfizer. Participants will be randomly assigned to receive either semaglutide or tirzepatide by subcutaneous injection as active comparators, or berobenatide by subcutaneous injection as the experimental treatment. The study compares continuing weekly injections of semaglutide or tirzepatide with switching to a monthly injection of berobenatide. Treatment duration and dosing schedules are designed to assess weight maintenance over approximately 11 months. During the study, participants will be monitored for changes in body weight from baseline to 32 weeks, including percent change and overall weight change. Safety will be closely observed through reports of treatment emergent adverse events, serious adverse events, adverse events leading to discontinuation, and adverse events of special interest. Laboratory tests will also be conducted to check for any abnormalities. Total participation lasts about 11 months to capture these outcomes fully.
CONDITIONS
Brief Title
A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity
Research Team
P
Pfizer CT.gov Call Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here